See Why Surrozen Stock Is Surging On Tuesday

by Vandana Singh, Benzinga Editor

September 7, 2021 1:30 PM | 1 min read | Make a Comment

Stifel initiated coverage of Surrozen Inc SRZN with a Buy rating and $19 price target.
The regenerative medicine biotech started trading recently on NASDAQ via SPAC deal with Consonance-HFW Acquisition Corp.
The price target represents an upside of 75%.
The Company has two proprietary technology platforms that and it seeks to either activate or amplify wingless/integrated signaling to engender clinical benefit, analyst Dae Gon Ha writes.
With lead programs SZN-1326 in moderate-severe ulcerative colitis and SZN-043 in severe alcoholic hepatitis, the analyst thinks proof of concept may emerge from Phase 1b patient studies.
Price Action: SRZN stock is up 49.0% at $10.79 during the market session on the last check Tuesday.